A reversal agent to stop serious bleeding in patients treated with apixaban and rivaroxaban has been approved.
Oral rivaroxaban may be preferable to injections of low-molecular-weight heparins for patients being treated for cancer.
A study found that apixaban is a safe alternative to VKAs for ablation of atrial fibrillation.
Andaxanet alfa has shown effectiveness for patients needing hemostasis.
Three medical groups have issued guidelines for the use of anticoagulants during cardiac surgery.
The DOAC edoxaban can replace dalteparin for treating cancer patients with venous thromboembolism.
A protein called STUB1 may help prevent blood clots in patients with chronic kidney disease without causing bleeding complications.
Direct oral anticoagulants have expanded treatment options for patients with venous thromboembolisms, but they are not for everyone.
A large Norwegian cohort study has found that warfarin is associated with a reduced risk of cancer.
Dialysis patients are often treated with direct oral anticoagulants, despite little research in this population.